Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 211280
Company: ELI LILLY AND CO

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
REYVOW LASMIDITAN SUCCINATE EQ 50MG BASE TABLET;ORAL Prescription None Yes No
REYVOW LASMIDITAN SUCCINATE EQ 100MG BASE TABLET;ORAL Prescription None Yes Yes
REYVOW LASMIDITAN SUCCINATE EQ 200MG BASE TABLET;ORAL Discontinued None Yes No

Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes
10/11/2019 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD Federal Register Notice
Label (PDF)
Letter (PDF)
Review
FR Notice on DEA Scheduling; Date of Approval – January 31, 2020
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note
06/03/2021 SUPPL-5 Labeling-Package Insert Label (PDF)
Letter (PDF)
07/17/2020 SUPPL-1 Labeling-Container/Carton Labels, Labeling-Package Insert, Labeling-Medication Guide Label (PDF)
Letter (PDF)

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert		 Note
06/03/2021 SUPPL-5 Labeling-Package Insert Label (PDF)
07/17/2020 SUPPL-1 Labeling-Container/Carton Labels Label (PDF)
07/17/2020 SUPPL-1 Labeling-Package Insert Label (PDF)
07/17/2020 SUPPL-1 Labeling-Medication Guide Label (PDF)
10/11/2019 ORIG-1 Approval Label (PDF)

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English